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A B S T R A C T
Hypoxia is an important feature of the microenvironment of a wide range of solid tumours.
Its critical role in radio- and chemoresistance and its significance as an adverse prognostic
factor have been well established over the last decades. On a cellular level, hypoxia evokes
a complex molecular response with a central role for the HIF-1 pathway. The cellular
processes under control of HIF-1 contain important prognostic information and comprise
potential candidates for directing hypoxia-modifying therapies. This review will provide
an overview of the current knowledge on the molecular aspects of tumour hypoxia and
the link to clinical practice.
ª 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
The tumour microenvironment is of great importance, influ-
encing malignant cells in various ways (Hu and Polyak,
2008). Within this microenvironment, hypoxia is an exten-
sively studied parameter, with relevance in almost all types
of solid tumours. As early as 1936 Mottram mentions the
relative insensitivity of tumours under anaerobic conditions
(Mottram, 1936). Gray described in 1953 the presence of hyp-
oxia in murine tumour cells and the associated reduced sensi-
tivity to radiotherapy (Gray et al., 1953). Hypoxia has negative
implications for clinical outcome. This is probably based on
two distinct principles: hypoxic cells are more resistant to
radiotherapy and chemotherapy, and they give rise to genetic
instability and more aggressive phenotypes.
Especially the increased resistance to radiotherapy is awell-
known phenomenon associated with tumour hypoxia, most
studied in head and neck cancer and cervical carcinoma
(Hockel et al., 1996; Nordsmark et al., 2005). Besides this
increased resistance to radiotherapy, there is evidence that
hypoxic cells are responsible for decreased sensitivity to
certain chemotherapeutic agents as well, such as doxorubicin,
5-fluorouracil andmethotrexate.Thesedataaremainlyderived
from animal and in vitro studies (Grau and Overgaard, 1992;
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Matthews et al., 2001;Wilsonet al., 1989). There is scarce recent
literature available on this subject.
Besides this resistance to chemo- and radiotherapy, surgi-
cally treated soft-tissue sarcomas and cervical carcinomas
also exhibit hypoxia as a prognostic factor for poor survival
(Hockel et al., 1996; Nordsmark et al., 2001). A correlation
was found between the rate of distantmetastases and tumour
oxygenation in soft-tissue sarcoma (Brizel et al., 1996).
Furthermore, in cervical cancer it has been proven that
hypoxic tumours exhibit more frequent parametrial spread
and lymph-vascular space involvement (Hockel et al., 1996).
A subgroup of hypoxic tumours with diminished apoptotic
potential showed increased lymphatic spread and higher
probability of recurrence as well (Hockel et al., 1999). These
findings indicate that hypoxia stimulates tumour cells to
develop towards a more invasive phenotype.
The measurement of hypoxia has been the subject of
investigation for years, and oxygen electrode measurement
has been considered the gold standard for sometime. 2-
Nitroimidazoles, such as pimonidazole and EF5, are exoge-
nous hypoxic cell markers, which bind to viable hypoxic cells
in vivo. Analysis of these exogenous hypoxic cell markers has
largely replaced the oxygen electrode as standard assay for
quantifying hypoxia. Theyhave gained interest as a prognostic
factor, although with varying results (Evans et al., 2007;
Kaanders et al., 2002c; Nordsmark et al., 2006). Now the
main research focus is on exploring the potential of endoge-
nous hypoxia-related markers, like hypoxia-inducible factor-
1 (HIF-1), carbonic anhydrase IX (CAIX), glucose transporters
(GLUT-1 and GLUT-3), plasminogen activator inhibitor-1
(PAI-1), vascular endothelial growth factor (VEGF) and osteo-
pontin (OPN). Most of these proteins are under control of the
HIF-1 pathway, which plays a central role in the cellular adap-
tation to hypoxic conditions. Another important adaptive
mechanism is the unfolded protein response (UPR). Impair-
ment of the tumour oxygenation status can lead to the accu-
mulation of misfolded proteins in the endoplasmatic
reticulum (ER). The accumulation of unfolded proteins acti-
vates the UPR, which may inhibit apoptosis. These cellular
responses to hypoxia are complex, with many different genes
and proteins involved. In this review the background and
prognostic and predictive value of the potential markers will
be discussed. Elucidating more about the response to hypoxia
and establishing the value of the different markers may lead
to the development of a predictive profile that enables the
selection of patients for hypoxia-modifying treatments.
2. Pathophysiology
Inmostmalignant tumours there is an imbalance between the
supply and consumption of oxygen, leading to hypoxic and
even anoxic regions. During the rapid growth of a tumour an
aberrant, chaotic microvasculature develops. Tumours
exhibit a vascular network with a wide range of vessel diam-
eters, intervascular distances and interbranching distances
unlike those seen in normal tissue (Konerding et al., 1995).
The morphological and functional deformed blood vessels di-
minish the oxygen delivery to the tumour cells, resulting in
a low oxygen microenvironment. Another factor contributing
to a decrease in oxygen supply is tumour-associated and ther-
apy-induced anaemia, leading to a diminished oxygen trans-
port capacity of the blood (anaemic hypoxia) (Vaupel et al.,
2001).
From a pathophysiological point of view hypoxia can be
divided into acute, or perfusion-limited hypoxia and chronic,
or diffusion-limited hypoxia, although this division is some-
what arbitrary (Dewhirst, 1998). Acute hypoxia is often tran-
sient and is caused by a temporary disruption in blood flow
as a result of an occlusion or rise in interstitial fluid pressure.
In xenografts only a small part of the tumour hypoxia is of the
intermittent type (Bennewith and Durand, 2004).
Chronic hypoxia arises with an increased diffusion dis-
tance of tumour cells from the microvessels (>70 mm) in the
distorted architecture of the vascular network. Acute and
chronic hypoxia combine in a heterogeneous pattern
throughout the tumour so that severe, intermediate and low
levels of hypoxia can be identified. From a clinical standpoint
it has been proposed that the intermediate hypoxic cells are
the most important for prognosis (Wouters and Brown,
1997). These cells are resistant to therapy and still have the
ability to proliferate (Hoogsteen et al., 2005).
Because thedegreeofhypoxia isextremelyvariableonacon-
tinuous scale, a strict cut-off value to discriminate normoxic
from hypoxic cells does not exist. Critical metabolic processes
fail at different pO2-levels (Figure 1). A median O2 partial pres-
sure of less than 10mm Hg already results in ATP depletion.
The oxidative phosphorylation gradually declines below this
value till it ceases at O2 partial pressures of less than
0.5 mmHg. Radioresistance may already occur below 25–
30 mmHg (Hockel and Vaupel, 2001). In most experiments,
values from 0.5 mmHg to 10mmHg have been used as a cut-
off value to discriminate normoxic from hypoxic tumour cells.
3. Measuring hypoxia
Over the years different methods have been developed for
assessing the level of hypoxia in tumours in vivo, with the
polarographic oxygen electrode mostly used as the gold stan-
dard. However, the disadvantage of this method led to the
development of less invasive techniques. Nowadays, the focus
has shifted to exogenous markers, like EF5 and pimonidazole
and a wide range of hypoxia-related endogenous markers
(Figure 2). Measuring hypoxia with imaging modalities such
as magnetic resonance imaging (MRI) and positron emission
tomography (PET) is another promising field of research.
3.1. Imaging hypoxia
The non-invasive assessment of tumour hypoxia is an active
area of research, with an emphasis on PET and blood oxygen-
ation level dependent magnetic resonance imaging (BOLD-
MRI) as promising modalities (review by Padhani et al., 2007).
With PET it is possible to quantify hypoxia in a well-
tolerated non-invasive procedure with the use of short-lived
positron emitting radionuclides. Several 18F- or 64Cu-
containing compounds have been developed to estimate the
hypoxic fraction, like 18F-EF1, 18F-MISO and 60/64Cu-ATSM,
with 18F-MISO being the most widely used and investigated.
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These tracers have been tested in several clinical studies for
their prognostic and predictive value, showing encouraging
results (Dehdashti et al., 2003; Rajendran et al., 2006). Eventu-
ally, hypoxia guided radiotherapy with radiation dose distri-
butions shaped to the hypoxic image, in such a way that the
most hypoxic regions of a tumour receive the highest radia-
tion dose, could be a strategy to obtain better tumour control.
BOLD-MRI is an experimental technique for detecting hyp-
oxia with good spatial and temporal resolution (Rijpkema
et al., 2002). It is based on the paramagnetic properties of
deoxyhaemoglobin, offering a way to indirectly visualise the
pO2 in blood vessels and surrounding tissue. An added advan-
tage is that the administration of contrast material can be
omitted. Unfortunately, it does not provide quantitative infor-
mation about the oxygen concentration, a major drawback of
all these techniques. Further investigation is necessary to val-
idate this method and establish its clinical importance.
3.2. Polarographic needle electrode
Being regarded as the gold standard for a long time, the polar-
ographic oxygen electrodehas been extensively used for quan-
tifying hypoxia in both animal studies and human tumours
(Brizel et al., 1997; Gatenbyet al., 1988).With this invasive tech-
nique oxygen concentrations can be measured directly at
many different positions in the tumour and within a short
time frame. Although the Eppendorf electrode, introduced in
the late 1980s, is a vast improvement compared to the older
systems, themethod still has somemajor drawbacks. It is lim-
ited to accessible tumour sites like head and neck and cervical
cancer, disrupts the tissue and it has a large inter-observer
variability (Nozue et al., 1997). Another restriction of this tech-
nique is the failure to distinguish necrotic areas from viable
tumour tissue and to discern the patterns of hypoxia.
3.3. Exogenous markers
The limitations of the needle electrode led to the development
of exogenous markers, the 2-nitroimidazoles, to measure
hypoxia. Two markers are approved for clinical use: pimoni-
dazole, (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole
hydrochloride, and EF5, [2-(2-nitro-1H-imidazole-1-yl)-N-
(2,2,3,3,3-pentafluoropropyl)acetamide]. These markers can
be administered intravenously and are reduced and bound
to thiol-containing proteins in viable hypoxic cells. Pimonida-
zole and EF5 have been proven to be reliable hypoxic markers,
with a good correlation with the radiobiologically hypoxic
fraction (Lee et al., 1996; Raleigh et al., 1999) and pO2 (Raleigh
et al., 1999).
Several studies have shown the prognostic value of the
2-nitroimidazoles in a clinical setting. In head and neck
cancer a correlation was found between the degree of
hypoxia estimated by 2-nitroimidazole binding and the
locoregional control and event-free-survival (Evans et al.,
2007; Kaanders et al., 2002c). One study performed in
patients with cervical carcinoma did not show this associa-
tion (Nordsmark et al., 2006) In patients with head and neck
cancer treated with ARCON (accelerated radiotherapy with
carbogen and nicotinamide), a hypoxia-modifying therapy,
pimonidazole demonstrated a predictive value as well
(Kaanders et al., 2002c).
An oral prescription of pimonidazole has become available,
which remains to be validated (Bennewith et al., 2002).
Recently, it has been FDA approved. For clinical use it would
be a progress, making the administration of pimonidazole
even more convenient.
3.4. Endogenous hypoxia-related markers
An alternative method not relying on injected markers to
quantify hypoxia is the use of endogenous markers, an
extensive range of potential markers having been studied
over the last years (Bussink et al., 2003). We prefer the term
hypoxia-related marker to hypoxic marker, as the associa-
tion between these markers and the oxygen status of the
tissue is weak and has only been reported in a few cases.
Endogenous markers are proteins upregulated in association
with hypoxia and can be measured in blood plasma or
Figure 1 – Cellular adaptation to hypoxia. The bars show the approximate hypoxic values below which cellular responses gradually change.
Figure adapted from Koumenis and Wouters (2006) and Hockel and Vaupel (2001).
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immunohistochemically on tumour biopsies. No single
marker has consistently demonstrated strong prognostic
power in clinical practice as of yet, although a correlation
with patient outcome has been found with CAIX, osteopontin
and PAI-1. Attempts have been made to combine various
markers to create a hypoxia-prognostic profile, with moder-
ate success (Koukourakis et al., 2006; Le et al., 2007). The
most important markers will be highlighted, with emphasis
on their role in the hypoxic molecular response and their
clinical significance.
Figure 2 – Photomicrographs of two human squamous-cell carcinoma xenograft cell lines (SCCNij51 and SCCNij58) after immunofluorescent
staining. The images show the differences in colocalisation of the exogenous marker pimonidazole (A and B) and three endogenous
hypoxia-related markers: CAIX (C and D), GLUT-1 (E and F) and GLUT-3 (G and H) (all in green), relative to the vasculature (in red).
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3.4.1. HIF-1
Hypoxia initiates a complicated response involving a plethora
of different molecular pathways. These pathways modulate
several cellular functions, like proliferation, apoptosis, angio-
genesis, pH balance and anaerobic glycolysis. The HIF-1 path-
way with its numerous downstream targets is the key
controller in this reaction (Figure 3). The transcription factor
HIF-1 is a heterodimer consisting of two subunits: HIF-1a
and HIF-1b. HIF-1b is constitutively active, while HIF-1a is
rapidly degraded under normoxic conditions and stabilised
by hypoxia (Wang et al., 1995). Upon activation HIF-1 binds
to the hypoxia responsive element (HRE), thereby promoting
the transcription of numerous genes including VEGF and the
genes encoding for the glucose transporters. Several cofactors
are involved in the transcriptional regulation of the various
target genes.
Under normoxic conditions two inhibitory pathways of
HIF-1a are essential. Prolyl hydroxylases (PHDs) hydroxylate
proline sites in the oxygen-dependent degradation domain
(ODD) of the HIF-1a protein. This enables binding of the von
Hippel Lindau protein (VHL), which leads to the proteasomal
degradation of HIF-1a. Under hypoxic conditions hydroxyl-
ation does not occur, leading to accumulation of HIF-1. The
second main inhibitory pathway of HIF-1a is factor inhibiting
HIF-1 (FIH-1). FIH-1 hydroxylates the C-terminal transactiva-
tion domain (CAD) of HIF-1a, which inhibits binding of p300/
CBP to the HIF-1 complex, which is a cofactor necessary for
transcription. Besides the oxygen-dependent activation of
HIF-1a, certain receptors of the tyrosine kinase family, like
insulin-like growth factor receptor (IGFR), epidermal growth
factor receptor (EGFR) and HER2/neu, can activate HIF-1a in
an oxygen-independent way. They regulate the transcrip-
tional activity through the P13 K/Akt/mTOR pathway
(Semenza, 2000).
HIF-1a has gained interest as an endogenous hypoxia-
related marker, after the discovery of its overexpression in
a wide variety of malignant tumours (Zhong et al., 1999). Its
significance as a prognostic factor for aggressive tumour
behaviour has been proven in various types of cancer; clear
cell carcinoma, ovarian carcinoma, gastric carcinoma, breast
cancer, soft-tissue sarcoma, bladder cancer, head and neck
cancer, rectal, lung cancer and cervical carcinoma (Moon
et al., 2007), although some studies show an opposite effect
(Beasley et al., 2002; Fillies et al., 2005). Moreover, the correla-
tion between HIF-1a expression and oxygen electrode or
pimonidazole measurements is weak (Mayer et al., 2004).
Therefore, the value of HIF-1a quantification as a hypoxia-
related assay remains questionable.
Given thewidespread overexpression of HIF-1 and its influ-
ence onmultiple cellular functions, it is a promising therapeu-
tic target, although the heterogeneity of the gene response
also makes it a complex target. Drugs aimed at the HIF-1
Figure 3 – Schematic representation of the HIF-1 pathway. Under normoxic conditions HIF-1a is hydroxylated and rapidly degraded
(A). Under hypoxic conditions the HIF-1 complex is stabilised and initiates the transcription of its target genes. EGFR can activate HIF-1a in
an oxygen-independent way (B).
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pathway can intervene in multiple ways; decreasing HIF-1a
mRNA or protein levels, inhibiting DNA binding of HIF-1 or de-
creasing HIF-1-mediated transactivation (Semenza, 2007). So
far, clinical studies show limited success of these approaches.
3.4.2. Carbonic anhydrase IX
One of the downstream targets of HIF-1 is carbonic anhydrase
9 (CA9). The upregulation of CA9 under hypoxic conditions is
controlled by the HIF-1 binding at the hypoxia responsive ele-
ment (HRE) in its promoter region (Figure 3). This is supported
by the fact that in VHL-defective renal cell carcinoma, in
which the inhibition of HIF-1 is lost, extensive overexpression
of CAIX can be found (Grabmaier et al., 2004). CAIX is one of
the 14 members of the CA-family, existing of cytosolic, mem-
brane-associated, mitochondrial and secreted carbonic anhy-
drases (Potter and Harris, 2003). CAIX (or MN, or G250) is
amembrane-associated enzymewith a zinc-containing extra-
cellular catalytic domain. This highly active domain catalyses
the reversible hydration of carbon dioxide to carbonic acid:
H2OþCO24HþþHCO3. It is involved in the respiratory gas
exchange and acid–base balance, maintaining the intracellu-
lar and lowering the extracellular pH. CAIX can form a close
interaction with certain ion-transport systems, the so-called
metabolons. The association with the bicarbonate transporter
is recently established, affirming the role of CAIX in ion-
transport and electrolyte-secretion (Morgan et al., 2007).
CAIX is only limitedly present in normal tissue; it is found
in gastric mucosa, small intestine and muscle. The overex-
pression of CAIX is demonstrated in different types of cancer
(Ivanov et al., 2001). The CAIX-positive cells are mainly pres-
ent in the perinecrotic areas of a tumour, in contrast with
tumours with inactivated VHL, where a more general staining
pattern is observed (Wykoff et al., 2000). The expression shows
overlapwith the staining pattern of pimonidazole, but a strong
correlation is not present (Kaanders et al., 2002c; Troost et al.,
2005). There is no correlation between the amount of CAIX and
direct oxygen measurement with the needle electrode in cer-
vical carcinoma (Mayer et al., 2005a). Notwithstanding, CAIX
has proven to be a prognostic marker in various tumours, as
high CAIX expression is associated with worse locoregional
control and overall survival (Potter and Harris, 2003). Espe-
cially, the combination of CAIX and a proliferation marker
such as IdUrd or Ki67, showed encouraging results. These
markers identify cells that are proliferating under hypoxic
conditions, perhaps themost crucial subpopulation of tumour
cells (Hoogsteen et al., 2005; Kim et al., 2007). In breast cancer,
a quantifying assay of CAIX could identify patients whowould
respond least to adjuvant treatment, demonstrating its
predictive value as well (Span et al., 2003).
Blocking the function of CAIX, resulting in an extracellular
rise in pH, can be an interesting approach in cancer treatment.
An acid tumour microenvironment can add to increased che-
moresistance, decreasing the uptake and consequently the
cytotoxicity of chemotherapeutic agents and enhances meta-
static potential (Tredan et al., 2007). Specific inhibitors of CAIX
have been developed, of which the sulphonamides are most
promising. Indisulam, a potent inhibitor of CAIX is under cur-
rent clinical investigation (Talbot et al., 2007). Furthermore,
a few monoclonal antibodies to block CAIX are under investi-
gation in renal cell carcinoma (Davis et al., 2007; Stillebroer
et al., 2007), a perfect candidate for these studies, considering
the high CAIX-overexpression found in this tumour type.
3.4.3. Glucose transporters
Another group of genes that is upregulated in hypoxic condi-
tions is that of genes encoding for the glucose transporters
(GLUTs). These transmembrane glycoproteins are omnipres-
ent in normal tissue, facilitating glucose transport across the
cell membrane. Malignant tumours generally have a higher
rate of metabolism, are more dependent on glycolysis as an
energy source (Warburg effect) and therefore have a higher
glucose need. Under hypoxic conditions the cell’s demand
for glucose increases as the anaerobic glycolysis becomes
even more important. This also involves recruitment and
overexpression of the glucose transporters inmanymalignant
(hypoxic) tumours. The two glucose transporters most associ-
ated with invasive cancer are GLUT-1 and GLUT-3, being over-
expressed in cervical carcinoma, head and neck cancer,
colorectal and bladder cancer (Macheda et al., 2005). A third
participant has been discovered more recently in breast and
prostate cancer: GLUT-12 (Rogers et al., 2002).
The comparison of immunohistochemical staining on
biopsies of cervical carcinoma of GLUT-1 and pimonidazole
showed similar staining patterns (Airley et al., 2003), but
a strong correlation with pO2 measurements by Eppendorf
histography has never been found. Several studies have
assessed the applicability of the glucose transporters as prog-
nostic markers. In cervical carcinoma high GLUT-1 expression
has been associated with lower metastasis-free-survival (Air-
ley et al., 2001), although in another study this correlation was
not overtly present (Mayer et al., 2005b). Additionally, in inva-
sive bladder cancer, high GLUT-1 expression has been shown
to be associated with poor survival (Palit et al., 2005). GLUT-1
and GLUT-3 have been proposed as prognostic factors in
head and neck cancer, but with equivocal conclusions (Baer
et al., 2002; Jonathan et al., 2006; Oliver et al., 2004). Summariz-
ing, GLUT expression has some prognostic potential in solid
tumours, but it is not a very robust hypoxia-related marker.
3.4.4. VEGF
VEGF is one of the genes upregulated by HIF-1 in a hypoxic
microenvironment. It can also be activated in an oxygen-
independentway through the PI3K-AKT pathway, for example
by EGFR or loss of PTEN (Bussink et al., 2008; Mizukami et al.,
2007; Pore et al., 2004). VEGF plays a crucial role in angiogene-
sis, physiologically and also pathologically in malignant
tumour growth (review by Ferrara et al., 2003). VEGF activates
signalling pathways like the Ras-Raf-MAPK and the PI3K-AKT
pathway and increases urokinase-type plasminogen activator
(uPA), tissue-type plasminogen activator (tPA) and plasmino-
gen activator inhibitor-1 (PAI-1) expression (see Section
3.4.5), thereby influencing tumour progression andmetastatic
spread in multiple ways. Of the two tyrosine kinase receptors
for VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1), the latter seems
the most important in enhancing mitosis of endothelial cells
and angiogenesis (Ferrara et al., 2003).
The expression of VEGF in different tumour types and its
significance for prognosis has been investigated in numerous
studies (as reviewed by Moon et al., 2007). Almost all of them
showed a correlation of VEGF with poor prognosis. Several
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VEGF- and VEGFR-inhibiting drugs have been developed and
tested in vitro and in vivo (Petersen, 2007). For instance
SU5416, a selective Flk-1 inhibitor (Fong et al., 1999) exhibited
a substantial anti-tumour activity when combinedwith irradi-
ation (Schuuring et al., 2005). Bevacizumab is a monoclonal
antibody against VEGF, approved for use in stage IIIB/IV non-
small cell lung cancer, which in a phase III ECOG trial showed
improved progression-free survival when combined with
chemotherapy (Sandler et al., 2006). As the absolute benefit
of these monoclonal antibodies is small, the main focus is
now on developing multitargeted receptor tyrosine kinase
inhibitors (RTKI), like vandetanib, which inhibits EGFR and
RET besides VEGFR (Hanrahan and Heymach, 2007). These
compounds are currently under investigation in clinical phase
III trials.
3.4.5. uPA/uPAR system
Another important signal route that can add to the aggressive-
ness of the tumour is the urokinase plasminogen activator
(uPA) system (Dass et al., 2007). It includes uPA with its mem-
brane-bound receptor (uPAR), tPA and the inhibitors (PAIs).
UPA and tPA are serine proteases that catalyse the activation
of plasminogen in plasmin. Plasmin in turn can activatemany
other enzymes, among which the matrix metalloproteases.
Eventually, this leads to the degradation of the basement
membrane and extracellular matrix, enhancing invasion and
metastatic spread. Even though uPA can exhibit some func-
tions without binding to uPAR, it is most active when associ-
ated with its receptor.
PAI-1 and PAI-2 are two inhibitors of uPA and tPA. PAI-I
binds to the uPA/uPAR complex, leading to internalization of
the whole complex and degradation of uPA and PAI-1 in the
lysosomes, while uPAR is transported back to the cell mem-
brane (Figure 4).
uPA, uPAR and PAI-1 are all reported to be overexpressed in
malignant tumours (Dass et al., 2007). In addition to the inhib-
iting effect on uPA, PAI-1 manifests biological functions with
an inverse effect, like inhibiting apoptosis and stimulating
angiogenesis (Bajou et al., 2001; Kwaan et al., 2000). Another
interesting fact is the presence of a hypoxia responsive
element in the promoter region of the PAI-1 gene, suggesting
the possibility of upregulation of PAI-1 under hypoxic condi-
tions. This has been confirmed to occur in hepatoma and
head and neck cell lines (Fink et al., 2002; Schilling et al.,
2007). Both uPA and PAI-1 are associated with a higher relapse
rate and a poor survival in various types of cancer. In breast
cancer, a large meta-analysis showed a poor prognosis for
uPA and PAI-1 positive tumours (Look et al., 2002). The prog-
nostic value of uPA and PAI-1 in breast cancer is now being
assessed in a multicentre prospective trial, the node-negative
breast cancer (NNBC)-3 Europe trial, where participating cen-
tres can perform risk estimation for breast cancer patients
by the uPA and PAI-1 concentration in tumour tissue biopsies.
uPA/PAI-1 is the first novel protein biomarker combination
recommended for clinical routine use in breast cancer by the
current 2007 ASCO guidelines (Harris et al., 2007).
3.4.6. Osteopontin
OPN is an integrin-binding protein first identified in non-
collagenous bone matrix and is involved in several
physiological processes, such as cytokine production, cell
adhesion and cell migration. In cancer, OPN seems to add to
the aggressiveness and metastatic potential of tumour cells
(Rittling and Chambers, 2004). An important factor in this ma-
lignant progression is the activation of uPA andmatrix metal-
loproteases by OPN through the PI3K/Akt, the IKKa/b and the
MAPK pathways. Two domains of OPN, the integrin- and
CD44-binding domain, are involved in this process. In the
OPN glycoprotein these two domains are separated by a prote-
ase-sensitive site and become functionally active upon cleav-
age of this site by thrombin as two distinct proteins. Another
effect of the binding of OPN to the integrin receptor is the c-Src
kinase mediated activation of the EGFR, a tyrosine kinase
receptor belonging to the erbB growth factor receptor family,
that plays a crucial role in oncogenesis as well (Rangaswami
et al., 2006).
OPN gene expression is inversely correlated with that of
VHL, indicating the role of OPN as a hypoxia-related protein.
Figure 4 – The uPA/uPAR system; its activation, the effects and
the inhibitory action of PAI-1.
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This was confirmed by the correlation between high plasma
OPN levels and low tumour pO2 in patients with head and
neck cancer (Le et al., 2003).
Overexpression of OPN is present in many different types
of tumours (Brown et al., 1994; Coppola et al., 2004). Several
studies have been performed to evaluate the prognostic signif-
icance of OPN applying different methods: measuring the
plasma concentration, themRNA level or using immunohisto-
chemistry on tissue sections. In lung and breast cancer immu-
nohistochemically quantified OPN has been correlated with
poor prognosis (Chambers et al., 1996; Rudland et al., 2002).
Plasma osteopontin has been associated with poor outcome
in head and neck cancer, hepatocellular carcinoma and
recently renal cell carcinoma (Overgaard et al., 2005; Raman-
kulov et al., 2007; Zhang et al., 2006). In the DAHANCA 5 trial,
a randomised trial comparing radiotherapy alone with
radiotherapy combined with the hypoxia sensitiser nimora-
zole, it showed predictive value as well. Only patients with
a high plasma concentration of OPN had advantage of the
hypoxia-modifying therapy (Overgaard et al., 2005). As OPN
is not only involved in malignant disease, but also in
vascular and inflammatory disorders, its use as a hypoxia-
related marker and potential target for treatment remains
questionable.
3.5. Unfolded protein response
Cellular adaptation to hypoxic stress involves upregulation of
hypoxia responsive genes, along with a down regulation of
oxygen- and energy-consuming processes, such as cell prolif-
eration and protein synthesis. The unfolding protein response
plays an important role in converting the cell into a low energy
state (recent review by Koumenis and Wouters, 2006).
In the cell mRNA translation, post-translational modifica-
tion and protein folding takes place in the endoplasmatic
reticulum (ER). In times of ER stress, like hypoxia, accumula-
tion of incorrectly folded proteins occurs. This initiates the
unfolded protein response, which leads to down regulation
of protein synthesis, increased degradation of unfolded
proteins and, during prolonged ER stress, activation of proa-
poptotic genes. The reduction in protein synthesis can be
attributed predominantly to a decrease in mRNA translation.
Themainmediator in this response is protein kinase activated
by dsRNA (PKR)-like endoplasmatic reticulum kinase (PERK),
which phosphorylates and thereby inactivates eukaryotic
initiating factor 2a (eIF2a), an important translation-initiating
factor (Figure 5). PERK is an ER-resident kinase that is normally
inactivated by glucose-regulated protein 78 (GRP78), a chaper-
one protein that dissociates from PERK under ER stress.
The ER transmembrane proteins IRE1 and activating tran-
scription factor-6 (ATF6) regulate the expression of the UPR
and ER stress genes, also the second function of PERK. IRE1
activates the transcription factor XBP-1, which is transported
subsequently to the nucleus to upregulate the UPR and ER
stress genes. ATF6 exhibits the same function as a transcrip-
tion factor upon activation by proteolysis in the Golgi. GRP78
is associated with IRE1 and ATF6 as well, inactivating them
in the absence of ER stress.
In xenografts with reduced GRP78, an suppression of tu-
mour growth, an increase of apoptosis and an inhibition of in-
vasion is observed (Lee, 2007). Furthermore, knockdown of
GRP78enhancessensitivityof tumourcells tochemotherapeutic
Figure 5 – The three main mediators in the unfolded protein response (UPR). PERK, IRE1 and ATF6 effectuate a decrease in protein synthesis
and an upregulation of UPR and ER stress genes.
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drugs by increasing apoptosis. In many different types of can-
cer GRP78 is a negative prognostic factor, with the exception of
neuroblastoma and lung cancer, in which it is associated with
a favourable outcome (Lee, 2007). GRP78 might be used in the
future as a predictivemarker in breast cancer to select patients
for adjuvant chemotherapy.
Inactivation of PERK or eIF2a in vitro and in xenografts also
results in an increased susceptibility to hypoxia and low cell
survival (Blais and Bell, 2006). PERK or IRE1 inhibitors could
be combined with other cytotoxic therapies as a novel
approach in anti-cancer treatment.
4. Targeting hypoxia
Given the complexity of the hypoxic response, various strate-
gies have been devised to target hypoxic cells. The most
straightforward strategy is increasing the oxygen availability.
Furthermore, some therapies have been developed using hyp-
oxic cell specific toxins, others are aimed at decreasing their
resistance to radiotherapy. A new field of research involves
the development of drugs that target proteins involved in
the hypoxic response or angiogenesis.
4.1. Increasing oxygen availability
One of the first attempts to overcome hypoxia involved deliv-
ery of radiotherapy in hyperbaric oxygen chambers. In head
and neck and cervical cancer patients treated with hyperbaric
oxygen showed improved local tumour control and survival
(Dische, 1978). This treatment was eventually abandoned as
hypoxia-modifying therapy due to the complex technique
and poor patient compliance.
The next step was to combine anti-cancer treatment such
as radiotherapy with normobaric oxygen or carbogen (95%
oxygenþ 5% carbon dioxide) breathing. ARCON (accelerated
radiotherapy with carbogen and nicotinamide) combines
radiotherapy with carbogen breathing and nicotinamide, a
vasoactive agent, counteracting both diffusion-limited and perfu-
sion-limited hypoxia (Kaanders et al., 2002a). In a phase II trial
of head and neck cancer it demonstrated a substantial thera-
peutic effect in laryngeal carcinoma, notably in the more
advanced tumour stages. The 3-year local control rate was
84% for T4 tumours, compared to around 50% with radiother-
apy alone (Kaanders et al., 2002b). Recently, two large phase III
trials on laryngeal cancer and bladder cancer were completed.
These trials will elucidate the potential benefit of ARCON as
hypoxia-modifying regimen.
4.2. Hypoxic cytotoxins
Bioreductive drugs, like tirapazamine (TPZ), exhibit a direct
cytotoxic effect on hypoxic cells. In the absence of oxygen,
reduction of TPZ takes place, forming a highly reactive radical,
which induces DNA damage. TPZ has proven its therapeutic
value in combination with cisplatin in a phase III randomised
trial in stages IIIB and IV non-small-cell lung cancer, increas-
ing the 1-year survival from 23% to 34% (von Pawel et al., 2000).
Conversely, the combination of TPZwith paclitaxel and carbo-
platin showed an increase in toxicity without any survival
advantage in advanced stage lung cancer (Williamson et al.,
2005). In advanced head and neck cancer, a phase II trial com-
paring TPZ, cisplatin and radiotherapy with 5-fluorouracil, cis-
platin and radiotherapy showed increased failure-free
survival rates with acceptable toxicity (Rischin et al., 2005).
The results from phase III trials are forthcoming; hopefully
these will clarify the clinical benefits of tirapazamine.
4.3. Radiosensitisers
Nitroimidazoles are chemical compounds that mimic the
radiosensitising effect of oxygen by inducing free-radical
mediated double strand DNA breaks. The use of the first gen-
eration drug misonidazole, the most thoroughly documented
of the nitroimidazoles, is obsolete in clinical practice as
a radiosensitiser, due to its severe side effects. However, it still
has the attention of some researchers as a PET-imaging com-
pound at substantially lower doses. Of the other nitroimida-
zoles, nimorazole has proven its value as a hypoxic cell
sensitising agent. In the Danish Head and Neck Cancer 5
study, in which 422 patients with head and neck cancer
were randomised, the locoregional control rate was signifi-
cantly higher (49% versus 33%) when radiotherapy was com-
bined with nimorazole compared to radiotherapy alone
(Overgaard et al., 1998). Nimorazole has not been adopted
widespread as a standard treatment despite these promising
results. The many negative studies with the older nitroimida-
zoles have contributed to this circumstance and a second
randomised trial has never been performed.
4.4. Vascular targeting
The vascular network of a tumour, providing oxygen and
nutrients, for long time has been an intriguing target in cancer
treatment. Twomain ways of vascular targeting can be distin-
guished: interfering in the angiogenesis, thereby preventing
the formation of new blood vessels, and destroying the exis-
tent vasculature. The angiogenesis-inhibitors have already
been discussed in the paragraph above on VEGF. For the sec-
ond approach, a broad range of vascular drugs is under devel-
opment, the so-called vascular disrupting agents (VDAs).
These compounds are aimed at the endothelium, causing
blood vessel occlusion resulting in extensive tumour necrosis.
The twomain groups of VDAs are the ligand-based agents and
the small molecules. The ligand-based agents are toxins or
pro-coagulants coupled to endothelium-directed antibodies,
peptides or growth factors. Most commonly used are the small
molecules, including the microtubulin destabilising drugs,
disrupting the cytoskeleton of the endothelial cells, and the
flavonoids, which causemassive cytokine production. Several
phase I studies have proven their applicability in clinical prac-
tice (Patterson and Rustin, 2007). These VDAs are not suffi-
ciently potent as a single agent therapy and therefore need
to be combined with chemo- or radiotherapy. An important
issue is the effect of the anti-vascular agents on tumour oxy-
genation, if it is combined with chemo- and radiotherapy. On
one side an increase in hypoxia is expected as the vasculariza-
tion is diminished. On the other side VDAs typically target the
tumour region with the most abnormal vasculature, usually
comprising the most hypoxic and hence radioresistant cells.
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Furthermore, there is evidence that VDAs can cause G2/M cell
cycle arrestwith associated enhanced radiosensitivity. In clin-
ical practice the VDAs have a small additive effect in combina-
tion with radiotherapy. CA4P (combretastatin-A4-phoshate)
and DMXAA (5,6-dimethylxanthenone-4-acetic acid) are two
small molecules that are currently under investigation in
phase II trials, combined with cytotoxic therapy. Several other
compounds are tested in phase I studies (review by Horsman
and Siemann, 2006).
5. Conclusion
With the abundant research performed on the molecular as-
pects of tumour hypoxia, several important pathways have
been elucidated over the last years. The hypoxic response is
complex with many genes and proteins involved that can be
important prognostic factors and interesting therapeutic tar-
gets. As of yet, no single marker has shown strong predictive
value to allow the selection of patients for hypoxia-modifying
treatment. Potential candidates, like pimonidazole and osteo-
pontin, could be the subjects of further research. Furthermore,
no single hypoxia-targeted drug has exhibited substantial
clinical effect as a single agent. Merging the different
approaches seems to be of pivotal importance, both in creat-
ing a predictive profile and developing a combined treatment.
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